The results showed that GAADPB appeared more sensitive than GALAD for detecting different HCC subgroups with very early/early stage (BCLC 0/A), small size (diameter < 3 cm), single lesion, absent PPVT, absent metastases, AFP-negative (20 ng/ml) and DCP-negative (<40 ng/ml), especially in (very) early-stage (BCLC 0/A), small size (diameter< 3 cm) and AFP-negative HCC, which improved its sensitivity by 12.1%, 12.5%, and 12.5% than GALAD, respectively. This evidence concerns the gene AFP and hepatocellular carcinoma.